Mgr Biostatistics-, Genetics Medicine and Rare Disease
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Manager Biostatistics Genetics Medicine & Rare Disease to join our Biostatistics Genetics Medicine and Rare Disease team, supporting Global Development in a hybrid work model. In this role, you will provide statistical leadership for clinical development programs while collaborating with Medical Directors, Clinical Scientists, Regulatory Affairs, Statistical Programming, Data Management, and Medical Writing.
Job description
Discover your role
- Partner with cross-functional teams to design and analyze clinical trials.
- Develop clinical study protocols, statistical analysis plans, and statistical methodologies.
- Collaborate with Statistical Programming on tables, figures, and listings for reporting.
- Analyze clinical and non-trial data to support program-level decisions.
- Interpret results and communicate findings through reports, presentations, and regulatory materials.
- Evaluate software and recommend novel statistical methods or analytical tools.
- Contribute to statistical innovation, infrastructure, process development, and training activities.
- You thrive in a collaborative environment and influence decisions through scientific insight.
This role requires
- PhD in Statistics/Biostatistics with 2+ years of pharmaceutical industry experience; or MS with 7+ years.
- Knowledge of drug discovery and development and application of statistical strategies.
- Solid expertise in statistical analysis methodology, experimental design, and clinical trial design.
- Proficiency with statistical software such as R or SAS.
- Experience developing protocols, statistical analysis plans, and clinical study analyses.
- Ability to interpret data and support regulatory reporting and decision-making.
- Strong leadership, influence, collaboration, communication, critical thinking, and time management skills.
- Ability to work effectively in a fast-paced cross-functional environment.
Requirements
- PhD in Statistics/Biostatistics with 2+ years of pharmaceutical industry experience; or MS with 7+ years
- Knowledge of drug discovery and development and application of statistical strategies
- Solid expertise in statistical analysis methodology, experimental design, and clinical trial design
- Proficiency with statistical software such as R or SAS
- Experience developing protocols, statistical analysis plans, and clinical study analyses
- Ability to interpret data and support regulatory reporting and decision-making
- Strong leadership, influence, collaboration, communication, critical thinking, and time management skills
- Ability to work effectively in a fast-paced cross-functional environment
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.